U. Kammula

Oncology · 2005–2014

A researcher in the Science corpus: 17 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Oncology — 92 citations into it; #1,335 of 1,698 by trust here, #100 by citations
• Immunology — 85 citations into it; #1,727 of 2,160 by trust here, #229 by citations

Whom U. Kammula trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Rosenberg

Who trusts U. Kammula overall

1. S. Rosenberg

Papers from U. Kammula's perspective

Ordered by how strongly the researchers U. Kammula trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Final version of 2009 AJCC melanoma staging and classification. (Journal of Clinical Oncology)
3. Adoptive cell transfer: a clinical path to effective cancer immunotherapy (Nature Reviews. Cancer)
4. Categorical Data Analysis
5. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (New England Journal of Medicine)
6. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
7. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
8. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. (Journal of Clinical Oncology)
9. IL-2: The First Effective Immunotherapy for Human Cancer (Journal of Immunology)
10. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (Blood)

Their papers

• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. (2005) — 987 citations
• Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (2013) — 1,094 citations
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007) — 631 citations
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014) — 728 citations
• Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. (2014) — 774 citations
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) — 1,404 citations
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011) — 1,972 citations
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) — 813 citations
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010) — 1,107 citations
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) — 1,438 citations
• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens (2008) — 1,357 citations
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007) — 703 citations
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. (2006) — 805 citations
• Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. (2006) — 841 citations
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) — 2,728 citations
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) — 1,709 citations